Trial of Dasatinib in Advanced Sarcomas
NCT00464620 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. As of 21 Nov 2026, it is completed. It studies Dasatinib in Chondrosarcoma, Chordoma and 8 more conditions. The registry lists an enrollment of 366 participants at 20 sites in 1 country. The registry lists a start date of 31 May 2007 and a primary completion date of 31 Dec 2016. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00464620 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration |
| Enrollment | 366 |
| Registered sites | 20 |
| Countries | 1 |
| Conditions | Chondrosarcoma, Chordoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST), Giant Cell Tumor of Bone, Hemangiopericytoma and 4 more conditions |
| Drugs | Dasatinib |
| Start | 31 May 2007 |
| Primary completion | 31 Dec 2016 |
| Study completion | 31 May 2017 |
| Last update posted | 23 Nov 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arkansas Children's Hospital
Little Rock
- City of Hope
Duarte
- Cedars-Sinai Outpatient Cancer Center
Los Angeles
- Stanford University
Palo Alto
- Sarcoma Oncology Center
Santa Monica
- Washington Cancer Institute
Washington D.C.
- Winship Cancer Institute at Emory University
Atlanta
- Kootenai Cancer Center
Coeur d'Alene
- Oncology Specialists
Park Ridge
- Indiana University Cancer Center
Indianapolis
- University of Iowa Hospitals and Clinics
Iowa City
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore
- Dana Farber Cancer Institute
Boston
- Massachusetts General Hospital
Boston
- University of Michigan
Ann Arbor
- Nebraska Methodist Hospital
Omaha
- Fox Chase Cancer Center
Philadelphia
- Pennsylvania Oncology Hematology Associates
Philadelphia
- University of Pittsburgh Cancer Institute
Pittsburgh
- Md Anderson
Houston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00464620
Each answer restates registry values shown on this page.
What is NCT00464620?
NCT00464620 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. It studies Dasatinib in Chondrosarcoma, Chordoma and 8 more conditions.
Who leads NCT00464620?
The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan) as the overall official.
Where does NCT00464620 run?
The registry lists 20 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00464620 study?
The registered drug and biological interventions are Dasatinib.
When did NCT00464620 end?
The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 May 2017. The sponsor last updated the record on 23 Nov 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.